Foundation Fighting Blindness: RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
October 26, 2024
October 26, 2024
COLUMBIA, Maryland, Oct. 26 -- The Foundation Fighting Blindness issued the following news:
* * *
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
* * *
Raleigh, NC - October 25, 2024 - The RD Fund (Retinal Degeneration Fund) - the venture arm of the Foundation Fighting Blindness - announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (N . . .
* * *
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
* * *
Raleigh, NC - October 25, 2024 - The RD Fund (Retinal Degeneration Fund) - the venture arm of the Foundation Fighting Blindness - announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (N . . .